DYNTQ · DYNATRONICS CORP
Substantial doubt about the company's ability to continue as a going concern.
“The Company's declining revenues, recurring operating losses and negative cash flows, and continued reduction in liquidity, raise substantial doubt about the Company's ability to continue as a going concern within one year after the issuance date of these condensed consolidated financial statements. The Company believes that if it successfully implements the foregoing strategic actions, it has a chance to mitigate the factors giving rise to substantial doubt; however, there is no guarantee that it will successfully implement these strategic actions. As a result, substantial doubt remains regarding the Company's ability to continue as a going concern.”View the 10-Q filed Nov 19, 2025
Price & Indicators
The closing range uses available history since Jan 5, 2026; less than a full year is stored.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DYNTQ
this stock
DYNATRONICS CORP
|
$1,604 | — | -15.8% | — | 0.0% |
|
ABT
Abbott Laboratories
|
$179.20B | -16.9% | +5.7% | 33.3 | 0.8% |
|
MDT
Medtronic plc
|
$118.67B | -3.4% | +8.4% | 22.9 | 3.1% |
|
SYK
Stryker Corp
|
$114.28B | -15.2% | +11.2% | 30.9 | 1.5% |
|
BSX
Boston Scientific Corp
|
$65.16B | -52.8% | +12.5% | 18.2 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 1.6%
- Net QoQ
- +76.6K sh
- Top holder
- RENAISSANCE TECHNOLOGIES…
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DYNTQ | -96.8% | -97.5% | — | +0.0% | — |
| SPY | +2.0% | +1.7% | +11.3% | +2.2% | +14.3% |
| vs SPY | -98.7% | -99.2% | — | -2.2% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.